Sodium Bicarbonate Plus N-Acetylcysteine Prophylaxis. A Meta-Analysis

JACC: Cardiovascular Interventions

Volumn 2, Issue 11, 2009, Pages 1116-1124

  Brown, Jeremiah R ^a,b   Block, Clay A ^b   Malenka, David J ^b   O'Connor, Gerald T ^a   Schoolwerth, Anton C ^b   Thompson, Craig A ^c  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

acute kidney injury; contrast; epidemiology; meta analysis; renal pharmacology

Indexed keywords

ACETYLCYSTEINE; ASCORBIC ACID; BICARBONATE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EVENING DOSAGE; HEART CATHETERIZATION; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; META ANALYSIS; MONOTHERAPY; MORNING DOSAGE; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REHYDRATION; RENAL REPLACEMENT THERAPY; RISK REDUCTION; SYSTEMATIC REVIEW;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; BIOLOGICAL MARKERS; CONTRAST MEDIA; CREATININE; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FREE RADICAL SCAVENGERS; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY DISEASES; KIDNEY FAILURE, ACUTE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL DIALYSIS; RISK ASSESSMENT; SODIUM BICARBONATE; TREATMENT OUTCOME;

EID: 70449506924     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2009.07.015     Document Type: Article

References (69)

1. Bui K.L., Horner J.D., Herts B.R., and Einstein D.M. Intravenous iodinated contrast agents: risks and problematic situations. Cleve Clin J Med 74 (2007) 361-364 367
2. Tumlin J., Stacul F., Adam A., et al. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 98 (2006) 14K-20K
3. Levy E.M., Viscoli C.M., and Horwitz R.I. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 (1996) 1489-1494
4. Gruberg L., Mintz G.S., Mehran R., et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 36 (2000) 1542-1548
5. McCullough P.A., Adam A., Becker C.R., et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 98 (2006) 5K-13K
6. McCullough P.A., Wolyn R., Rocher L.L., Levin R.N., and O'Neill W.W. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 103 (1997) 368-375
7. Mehran R., and Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl (2006) S11-S15
8. Chertow G.M., Burdick E., Honour M., Bonventre J.V., and Bates D.W. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16 (2005) 3365-3370
9. Rihal C.S., Textor S.C., Grill D.E., et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 105 (2002) 2259-2264
10. Stacul F., Adam A., Becker C.R., et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 98 (2006) 59K-77K
11. Brown J.R., DeVries J.T., Robb J.F., et al. Serious renal dysfunction after percutaneous coronary intervention can be predicted. Am Heart J 155 (2008) 260-266
12. Mehran R., Aymong E.D., Nikolsky E., et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 44 (2004) 1393-1399
13. Elicker B.M., Cypel Y.S., and Weinreb J.C. IV contrast administration for CT: a survey of practices for the screening and prevention of contrast nephropathy. AJR Am J Roentgenol 186 (2006) 1651-1658
14. Briguori C., Airoldi F., D'Andrea D., et al. Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation 115 (2007) 1211-1217
15. Recio-Mayoral A., Chaparro M., Prado B., et al. The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. J Am Coll Cardiol 49 (2007) 1283-1288
16. Arstall M.A., Yang J., Stafford I., Betts W.H., and Horowitz J.D. N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. Circulation 92 (1995) 2855-2862
17. Atkins J.L. Effect of sodium bicarbonate preloading on ischemic renal failure. Nephron 44 (1986) 70-74
18. Baroni E.A., Costa R.S., Volpini R., and Coimbra T.M. Sodium bicarbonate treatment reduces renal injury, renal production of transforming growth factor-beta, and urinary transforming growth factor-beta excretion in rats with doxorubicin-induced nephropathy. Am J Kidney Dis 34 (1999) 328-337
19. Brunet J., Boily M.J., Cordeau S., and Des Rosiers C. Effects of N-acetylcysteine in the rat heart reperfused after low-flow ischemia: evidence for a direct scavenging of hydroxyl radicals and a nitric oxide-dependent increase in coronary flow. Free Radic Biol Med 19 (1995) 627-638
20. Lindinger M.I., Franklin T.W., Lands L.C., Pedersen P.K., Welsh D.G., and Heigenhauser G.J. NaHCO(3) and KHCO(3) ingestion rapidly increases renal electrolyte excretion in humans. J Appl Physiol 88 (2000) 540-550
21. Sporer H., Lang F., Oberleithner H., Greger R., and Deetjen P. Inefficacy of bicarbonate infusions on the course of postischaemic acute renal failure in the rat. Eur J Clin Invest 11 (1981) 311-315
22. Brar S.S., Shen A.Y., Jorgensen M.B., et al. Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. JAMA 300 (2008) 1038-1046
23. Heguilen R., Liste A., Gabriela R., et al. Prevention of contrast-induced nephropathy: volume expansion, N-acethylcysteine or both?. Results from a pilot study. Nephrol Dial Transplant 22 (2007) 54-55
24. Kim G., Kim K., Shin J., Lee C.H., and Kang C.M. Hydration with sodum bicarbonate for the prevention of radiocontrast-induced nephropathy. Nephrol Dial Transplant 22 (2007) 49
25. Lin M., Sabeti M., Iskander E., Malhotra N., Phan P.T.T., and Phan P.C.T. Prevention of contrast nephropathy with sodium bicarbonate. J Am Soc Nephrol 18 (2007) 959A-960A
26. Maioli M., Toso A., Leoncini M., et al. Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. J Am Coll Cardiol 52 (2008) 599-604
27. Ruiz A.S., Marchetti G., Lagioia A., et al. Randomized study of evaluation of N-acetylcysteine and sodium bicarbonate in the prevention of contrast-induced nephropathy. Circulation 118 (2008) E295
28. Saidin R., Zainudin S., Kong N.C.T., Oteh K., Saaidin N.F., and Shah S.A. Intravenous sodium bicarbonate versus normal saline infusion as prophylaxis against contrast nephropathy in patients with chronic kidney disease undergoing coroanry artery angiography or angioplasty. J Am Soc Nephrol 17 (2006) 766A
29. Shaikh F., Maddikunta R., Museitif R., et al. A prospective randomized trial comparing normal saline and sodium bicarbonate with or without N-acetyleysteine for prevention of contrast-induced nephropathy. Am J Cardiol 100 (2007) 122L-123L
30. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., and Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 354 (1999) 1896-1900
31. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Cont Clin Trials 17 (1996) 1-12
32. Higgins J.P., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. Brit Med J 327 (2003) 557-560
33. Brown J.R., Birkmeyer N.J., and O'Connor G.T. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115 (2007) 2801-2813
34. Henry D.A., Moxey A.J., Carless P.A., et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochr Data Syst Rev (2001) CD001886
35. Solomon R., Werner C., Mann D., D'Elia J., and Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 331 (1994) 1416-1420
36. Mueller C., Buerkle G., Buettner H.J., et al. Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. Arch Intern Med 162 (2002) 329-336
37. Merten G.J., Burgess W.P., Gray L.V., et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 291 (2004) 2328-2334
38. Hogan S.E., L'Allier P., Chetcuti S., et al. Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. Am Heart J 156 (2008) 414-421
39. Joannidis M., Schmid M., and Wiedermann C.J. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. Wien Klin Wochenschr 120 (2008) 742-748
40. Navaneethan S.D., Singh S., Appasamy S., Wing R.E., and Sehgal A.R. Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Am J Kidney Dis 53 (2009) 617-627
41. Meier P., Ko D.T., Tamura A., Tamhane U., and Gurm H.S. Sodium bicarbonate-based hydration prevents contrast-induced nephropathy: a meta-analysis. BMC Med 7 (2009) 23
42. Tepel M., van der Giet M., Schwarzfeld C., Laufer U., Liermann D., and Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 343 (2000) 180-184
43. Alonso A., Lau J., Jaber B.L., Weintraub A., and Sarnak M.J. Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. Am J Kidney Dis 43 (2004) 1-9
44. Birck R., Krzossok S., Markowetz F., Schnulle P., van der Woude F.J., and Braun C. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 362 (2003) 598-603
45. Duong M.H., MacKenzie T.A., and Malenka D.J. N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis. Catheter Cardiovasc Interv 64 (2005) 471-479
46. Guru V., and Fremes S.E. The role of N-acetylcysteine in preventing radiographic contrast-induced nephropathy. Clin Nephrol 62 (2004) 77-83
47. Isenbarger D.W., Kent S.M., and O'Malley P.G. Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 92 (2003) 1454-1458
48. Liu R., Nair D., Ix J., Moore D.H., and Bent S. N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis. J Gen Intern Med 20 (2005) 193-200
49. Misra D., Leibowitz K., Gowda R.M., Shapiro M., and Khan I.A. Role of N-acetylcysteine in prevention of contrast-induced nephropathy after cardiovascular procedures: a meta-analysis. Clin Cardiol 27 (2004) 607-610
50. Bagshaw S.M., and Ghali W.A. Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: a systematic review and meta-analysis. BMC Med 2 (2004) 38
51. Kshirsagar A.V., Poole C., Mottl A., et al. N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. J Am Soc Nephrol 15 (2004) 761-769
52. Nallamothu B.K., Shojania K.G., Saint S., et al. Is acetylcysteine effective in preventing contrast-related nephropathy?. A meta-analysis. Am J Med 117 (2004) 938-947
53. Pannu N., Manns B., Lee H., and Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int 65 (2004) 1366-1374
54. Zagler A., Azadpour M., Mercado C., and Hennekens C.H. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials. Am Heart J 151 (2006) 140-145
55. Marenzi G., Assanelli E., Marana I., et al. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med 354 (2006) 2773-2782
56. Hoffmann U., Fischereder M., Kruger B., Drobnik W., and Kramer B.K. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 15 (2004) 407-410
57. Kelly A.M., Dwamena B., Cronin P., Bernstein S.J., and Carlos R.C. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 148 (2008) 284-294
58. Van Praet J.T., and De Vriese A.S. Prevention of contrast-induced nephropathy: a critical review. Curr Opin Nephrol Hypertens 16 (2007) 336-347
59. Abizaid A.S., Clark C.E., Mintz G.S., et al. Effects of dopamine and aminophylline on contrast-induced acute renal failure after coronary angioplasty in patients with preexisting renal insufficiency. Am J Cardiol 83 (1999) 260-263
60. Gare M., Haviv Y.S., Ben-Yehuda A., et al. The renal effect of low-dose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol 34 (1999) 1682-1688
61. Hans S.S., Hans B.A., Dhillon R., Dmuchowski C., and Glover J. Effect of dopamine on renal function after arteriography in patients with pre-existing renal insufficiency. Am Surg 64 (1998) 432-436
62. Weisberg L.S., Kurnik P.B., and Kurnik B.R. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 45 (1994) 259-265
63. Allaqaband S., Tumuluri R., Malik A.M., et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 57 (2002) 279-283
64. Stone G.W., McCullough P.A., Tumlin J.A., et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 290 (2003) 2284-2291
65. Cruz D.N., Perazella M.A., Bellomo R., et al. Extracorporeal blood purification therapies for prevention of radiocontrast-induced nephropathy: a systematic review. Am J Kidney Dis 48 (2006) 361-371
66. Marenzi G., Bartorelli A.L., Lauri G., et al. Continuous veno-venous hemofiltration for the treatment of contrast-induced acute renal failure after percutaneous coronary interventions. Catheter Cardiovasc Interv 58 (2003) 59-64
67. Lee P.T., Chou K.J., Liu C.P., et al. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. J Am Coll Cardiol 50 (2007) 1015-1020
68. Romano G., Briguori C., Quintavalle C., et al. Contrast agents and renal cell apoptosis. Eur Heart J 29 (2008) 2569-2576
69. Briguori C., Colombo A., Violante A., et al. Standard vs double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity. Eur Heart J 25 (2004) 206-211